ライムボレリア症ワクチン:世界の市場機会分析・予測

◆英語タイトル:MarketVIEW: Lyme Borreliosis vaccines - Lyme Borreliosis vaccines: global market forecast and size
◆商品コード:VAZ2006011
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2019年6月
◆ページ数:n/a
◆レポート言語:英語
◆レポート形式:Executive presentation (~210 slides .pdf) + 1 MS Excel
workbook (.xls)
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Region PriceUSD9,995 ⇒換算¥1,039,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
VacZine Analytics社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Lyme Borreliosis (LB) or Lyme disease is caused by an infection with the bacterial spirochete Borrelia genospecies. The pathogen is transmitted to humans through the bite of infected Ixodes tick species. LB, which is endemic in large areas of Europe and North America, can cause a wide range of disease symptoms which range from a mild treatable rash (erythema migrans, EM) to serious multistage complications of the neurological (neuroborreliosis) and musculoskeletal systems. Aside from increased awareness and testing, experts believe the incidence of LB is increasing partly due to expanding vector populations. There are an estimated 300,000 cases of Lyme disease annually each in the US and EU. The disease is significantly underreported and has high profile chronic implications for many individuals.
GSK Biologicals licensed an OspA-based recombinant vaccine (LYMErix) in 1998 which was later withdrawn due to several reasons. Both Baxter Vaccines and Sanofi Pasteur were developing OspA-based approaches, but development was halted. Valneva appear to have the only human Lyme Disease vaccine in development (VLA15) which is advancing through Phase II studies. There are many drivers to vaccine development but also controversies and challenges.

This MarketVIEW product is composed of a comprehensive Executive summary presentation (197 slides, .pdf) + MS Excel-based model which forecasts the potential commercial value of a putative Lyme Borreliosis vaccines across 27 major Western markets to 2040. Both adult and pediatric, as well as risk-persons,are considered with 3 pricing scenarios (LO, BASE and HI). A detailed review of disease background and epidemiology is included along with current treatment, unmet needs and rationale for vaccine approach with a review of the latest key working group viewpoints. Target Product Profiles (TPP) are defined based on recent R&D understanding, along with commercial model assumptions. This analysis is ideally suited to any organisation wishing to understand and justify new investment into this highly important opportunity.

THIS PRODUCT IS A SUMMARY PRESENTATION (.pdf, 197 slides) + 1 MODEL (.xls, >75 worksheets)

To order please contact your region account manager, buy “on-line” or order direct at: orders@vaczine-analytics.com

【レポートの目次】

PRODUCT CONTENTS:
Published June 2019 (CAT No: VAMV024)
****This product is a summary presentation (.pdf), a forecast model (.xls)
Contents – Summary presentation (.pdf)3
Contents
Author’s notes
Executive summary
[SECTION 1] Lyme Borreliosis vaccines: key commercial model outputs
[SECTION 2] Lyme Borreliosis: disease background
[SECTION 3] Lyme Borreliosis: disease epidemiology (US+EU), economic burden
[SECTION 4] Lyme Borreliosis: vaccine history and development
[SECTION 5] Lyme Borreliosis: estimating vaccine commercial potential
[SECTION 6] Lyme Borreliosis: detailed country epidemiological profiles
Bibliography (217 references)
Disclaimer
PAGES: ~210 slides fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)
Worksheets = >50 interconnected



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ライムボレリア症ワクチン:世界の市場機会分析・予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆